Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Expert Insights: The Future of Life Sciences Consultancy in Eastvale

Jan 28, 2025

Understanding the Current Landscape

The life sciences consultancy sector is experiencing a surge in demand as companies seek to navigate the complexities of healthcare regulations, technology advancements, and market dynamics. In Eastvale, a hub for biotechnology and pharmaceutical companies, this trend is particularly pronounced. The need for specialized knowledge and strategic guidance is driving the expansion of consultancy services.

Consultancies are playing a critical role in helping organizations address challenges such as drug development timelines, compliance with regulatory standards, and the integration of digital health solutions. As the industry continues to evolve, the role of consultancies is becoming more pivotal than ever.

life sciences industry

Technological Innovations Shaping the Future

Technology is a key factor influencing the future of life sciences consultancy. Advancements in artificial intelligence, machine learning, and big data analytics are transforming how companies approach research and development. Consultancies in Eastvale are increasingly leveraging these technologies to provide data-driven insights and predictive analytics that enhance decision-making processes.

The integration of digital tools is not only streamlining operations but also opening up new opportunities for personalized medicine and precision healthcare. This shift towards technology-driven solutions is expected to continue shaping the consultancy landscape in the coming years.

technology innovation

Regulatory Challenges and Opportunities

Regulatory compliance remains a significant challenge for life sciences companies. The ever-changing landscape of healthcare regulations requires organizations to stay agile and informed. Consultancies in Eastvale are stepping up to provide expert guidance on navigating these complexities, ensuring that companies remain compliant while pursuing innovation.

However, regulatory changes also present opportunities for consultancies to drive growth. By staying ahead of regulatory trends, consultancies can help clients identify potential risks and opportunities, thereby fostering a proactive rather than reactive approach to compliance.

The Role of Sustainability

Sustainability is becoming an essential consideration for life sciences companies worldwide. In Eastvale, consultancies are focusing on helping businesses adopt sustainable practices that not only meet regulatory requirements but also align with corporate social responsibility goals.

From reducing environmental impact to improving supply chain transparency, sustainability initiatives are increasingly being integrated into life sciences consultancy services. This focus on sustainability is likely to become more prominent as stakeholders demand greater accountability and transparency from organizations.

sustainable practices

Collaborative Approaches in Consultancy

The future of life sciences consultancy in Eastvale is also marked by increased collaboration between businesses, research institutions, and consultancies. By fostering partnerships, consultancies are able to offer more comprehensive solutions that draw on a diverse array of expertise and resources.

This collaborative approach not only enhances the value provided to clients but also accelerates innovation by facilitating knowledge exchange and cross-disciplinary research efforts. As a result, consultancies are positioned as key enablers of progress within the life sciences ecosystem.

collaborative work

Conclusion: Embracing Change for Growth

The life sciences consultancy sector in Eastvale is poised for significant growth as it adapts to the evolving needs of the industry. By embracing technological innovations, addressing regulatory challenges, prioritizing sustainability, and fostering collaboration, consultancies are well-equipped to lead their clients into the future.

As the landscape continues to change, staying informed and agile will be crucial for consultancies aiming to remain at the forefront of industry trends. With a commitment to innovation and excellence, life sciences consultancies in Eastvale are set to play a vital role in shaping the future of healthcare and biotechnology.